John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

IBD and epidemiology in 2023: new data Volume 30, issue 2, February 2023

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4
Authors
1 CHU de Saint-Étienne, Service d’hépato-gastro-entérologie, Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez
2 Hospices Civils de Lyon, Centre hospitalier Lyon-Sud, Service d’hépato-gastro-entérologie, 165 chemin du Grand Revoyet, 69310 Pierre-Bénite
* Correspondance : X. Roblin

If there are still great geographical disparities in the world concerning the incidence and prevalence of IBD and of its two subtypes, it is clear that we have experienced two epidemiological waves: a first wave in industrialized countries and a second not less important in emerging countries associated with a concept of "westernization" of dietary habits among others. We are at a stage of high prevalence due to a much higher incidence than mortality of these patients. However, IBD population is aging, and the rate of elderly patients is growing significantly, requiring strategies dedicated to these more frailty patients. Antibiotic intake and ultra-processed food are the two major points involved in the mechanistic of these diseases by impacting the microbiota, among other things.